{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:56:06Z","timestamp":1765486566620,"version":"3.41.2"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzhen","doi-asserted-by":"publisher","award":["SZSM201801060"],"award-info":[{"award-number":["SZSM201801060"]}],"id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> To evaluate the cost-effectiveness of adding daratumumab to bortezomib, melphalan, and prednisone for transplant-ineligible newly diagnosed multiple myeloma patients.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> A three-state Markov model was developed from the perspective of US payers to simulate the disease development of patient\u2019s life time for daratumumab plus bortezomib, melphalan, and prednisone (D-VMP) and bortezomib, melphalan, and prednisone (VMP) regimens. The primary outputs were total costs, expected life-years (LYs), quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs).<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The base case results showed that adding daratumumab to VMP provided an additional 3.00 Lys or 2.03 QALYs, at a cost of $262,526 per LY or $388,364 per QALY. Sensitivity analysis indicated that the results were most sensitive to utility of progression disease of D-VMP regimens, but no matter how these parameters changed, ICERs remained higher than $150,000 per QALY.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> In the case that the upper limit of willingness to pay threshold was $150,000 per QALY from the perspective of US payers, D-VMP was not a cost-effective regimen compared to VMP.<\/jats:p>","DOI":"10.3389\/fphar.2021.608685","type":"journal-article","created":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T05:54:58Z","timestamp":1614578098000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Cost-Effectiveness Analysis of Adding Daratumumab to Bortezomib, Melphalan, and Prednisone for Untreated Multiple Myeloma"],"prefix":"10.3389","volume":"12","author":[{"given":"Yaohua","family":"Cao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiantian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiling","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,1]]},"reference":[{"key":"B1","first-page":"1","article-title":"United States Life Tables, 2017","volume":"68","author":"Arias","year":"2019","journal-title":"Natl. Vital Stat. Rep."},{"key":"B2","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e478","DOI":"10.1016\/j.clml.2019.04.009","article-title":"Treatment outcomes in patients with newly diagnosed multiple myeloma who are ineligible for stem-cell Transplantation: systematic review and network meta-analysis","volume":"19","author":"Cao","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"B4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.18553\/jmcp.2018.24.1.29","article-title":"Cost-effectiveness of drugs to treat relapsed\/refractory multiple myeloma in the United States","volume":"24","author":"Carlson","year":"2018","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"B5","unstructured":"Center for Medicare and Medicaid Services. Clinical Laboratory Fee Schedule [Online]"},{"key":"B6","unstructured":"Center for Medicare and Medicaid Services. Medicare Part B Drug Average Sales Price [Online]"},{"key":"B7","unstructured":"Center for Medicare and Medicaid Services. Physician Fee Schedule [Online]"},{"key":"B8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"","journal-title":"Lancet Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"","journal-title":"N. Engl. J. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"E68","DOI":"10.1002\/ajh.25372","article-title":"Daratumumab vs pomalidomide for the treatment of relapsed\/refractory multiple myeloma: a cost-effectiveness analysis","volume":"94","author":"Gong","year":"2019","journal-title":"Am. J. Hematol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/hec.3871","article-title":"Frequentist and Bayesian meta-regression of health state utilities for multiple myeloma incorporating systematic review and analysis of individual patient data","volume":"28","author":"Hatswell","year":"2019","journal-title":"Health Econ."},{"key":"B13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/1471-2288-11-139","article-title":"Improved curve fits to summary survival data: application to economic evaluation of health technologies","volume":"11","author":"Hoyle","year":"2011","journal-title":"BMC Med. Res. Methodol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.6004\/jnccn.2019.0049","article-title":"NCCN guidelines insights: multiple myeloma, Version 1.2020","volume":"17","author":"Kumar","year":"2019","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"B15","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline","volume":"37","author":"Mikhael","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2013the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial","volume":"28","author":"Palumbo","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1016\/j.clinthera.2017.08.010","article-title":"Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the treatment of patients with heavily pretreated relapsed-refractory multiple myeloma in the United States","volume":"39","author":"Pelligra","year":"2017","journal-title":"Clin. Ther."},{"key":"B23","unstructured":"RED BOOK Online [Online]2020"},{"key":"B24","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"B25","doi-asserted-by":"crossref","unstructured":"Surveillance, epidemiology, and end results program:myeloma [Online]2020","DOI":"10.1155\/2020\/2809647"},{"key":"B26","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3111\/13696998.2015.1115407","article-title":"Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma","volume":"19","author":"Usmani","year":"2016","journal-title":"J. Med. Econ."},{"key":"B27","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1001\/jamaoncol.2018.7086","article-title":"First-line nivolumab plus ipilimumab vs sunitinib for metastatic renal cell carcinoma: a cost-effectiveness analysis","volume":"5","author":"Wan","year":"2019","journal-title":"JAMA Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1158\/1078-0432.CCR-17-3117","article-title":"Fratricide of NK cells in daratumumab therapy for multiple myeloma overcome by Ex vivo expanded autologous NK cells","volume":"24","author":"Wang","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.clinthera.2019.12.007","article-title":"Economic evaluation of adding daratumumab to a regimen of bortezomib + dexamethasone in relapsed or refractory multiple myeloma: based on the latest updated analysis of CASTOR","volume":"42","author":"Zeng","year":"2020","journal-title":"Clin. Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.clinthera.2018.05.012","article-title":"Cost-effectiveness of daratumumab-based triplet therapies in patients with relapsed or refractory multiple myeloma","volume":"40","author":"Zhang","year":"2018","journal-title":"Clin. Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/CAD.0b013e32836032d5","article-title":"Continuous treatment with new agents for newly diagnosed multiple myeloma","volume":"24","author":"Zou","year":"2013","journal-title":"Anticancer Drugs"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.608685\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T05:55:04Z","timestamp":1614578104000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.608685\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,1]]},"references-count":32,"alternative-id":["10.3389\/fphar.2021.608685"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.608685","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2021,3,1]]},"article-number":"608685"}}